Review of the Evidence for Treatment of Children with Autism with Selective Serotonin Reuptake Inhibitors

被引：29

作者：

West, Lis ^{[2
]}

Brunssen, Susan H. ^{[1
]}

Waldrop, Julee ^{[1
]}

机构：

[1] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27515 USA

[2] Carolina Pediat Grp, Fayetteville, NC USA

来源：

JOURNAL FOR SPECIALISTS IN PEDIATRIC NURSING | 2009年 / 14卷 / 03期

关键词：

Antidepressants; autism; pervasive developmental disorder; pharmacotherapy; psychopharmacotherapy; selective serotonin reuptake inhibitors; PERVASIVE DEVELOPMENTAL DISORDERS; PHARMACOLOGICAL-TREATMENT; OPEN-LABEL; ADOLESCENTS; TRANSPORTER; FLUOXETINE; SYMPTOMS; PATTERNS; HYPERACTIVITY; FLUVOXAMINE;

D O I：

10.1111/j.1744-6155.2009.00196.x

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

PURPOSE. To review the potential role of serotonin dysregulation in autism and the efficacy of selective serotonin reuptake inhibitors (SSRIs) in treating core deficits and associated symptoms of autism in children. The literature was searched for reports of SSRI use in children with autism. Data are presented from prospective clinical trials that evaluated treatment outcomes. CONCLUSIONS. Some SSRIs show moderate success in managing specific behaviors. Only fluoxetine shows evidence of decreasing global autism severity. PRACTICE IMPLICATION. Definitive conclusions concerning selection criteria, dosage, safety, and efficacy cannot be drawn given the current state of evidence.

引用

页码：183 / 191

页数：9

共 54 条

[1] PSYCHOTROPIC AND ANTICONVULSANT DRUGS IN SUBJECTS WITH AUTISM - PREVALENCE AND PATTERNS OF USE [J].